We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+14.51%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$997M
AUM Growth
+$109M
Cap. Flow
+$49.9M
Cap. Flow %
5.01%
Top 10 Hldgs %
74.49%
Holding
41
New
11
Increased
8
Reduced
8
Closed
10

Top Buys

1
RCUS icon
Arcus Biosciences
RCUS
+$37.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$24.2M
3
WVE icon
Wave Life Sciences
WVE
+$22M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
URGN icon
UroGen Pharma
URGN
+$20.2M

Top Sells

1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$16M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$10.3M
4
ONC
BeOne Medicines Ltd
ONC
+$8.18M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.62M

Sector Composition

1 Healthcare 87.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
26
Denali Therapeutics
DNLI
$3.7B
$6.4M 0.64%
325,000
+125,000
+63% +$2.57M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.31B
$6.34M 0.64%
318,564
-211,597
-40% -$5.62M
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$1.25B
$5.42M 0.54%
469,700
-118,732
-20% -$1.12M
LUMO
29
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.06M 0.41%
+62,222
New +$4.41M
KIN
30
DELISTED
Kindred Biosciences, Inc.
KIN
$2.15M 0.22%
248,680
-296,200
-54% -$2.6M
GERN icon
31
Geron
GERN
$924M
$1.49M 0.15%
+350,000
New +$946K
LKFT
32
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
– –
-110,384
Closed -$10.3M
MDGL icon
33
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-35,000
Closed -$3.21M
NTLA icon
34
CALL
Intellia Therapeutics
NTLA
$1.59B
– –
-75,000
Closed -$1.44M
QURE icon
35
CALL
uniQure
QURE
$2.77B
– –
-263,900
Closed -$5.17M
XNCR icon
36
Xencor
XNCR
$1.3B
– –
-112,976
Closed -$2.48M
ONC
37
BeOne Medicines Ltd
ONC
$32.4B
– –
-83,667
Closed -$8.18M
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-103,240
Closed -$1.88M
MYOK
39
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-778,393
Closed -$32.8M
ONCE
40
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-455,500
Closed -$23.4M
CMTA
41
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-194,166
Closed -$3.69M
1
2

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q1 2018 Portfolio in Review

As of Q1 2018, EcoR1 Capital held 41 positions worth $997M, up 12% from $888M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

EcoR1 Capital deployed $49.9M of net new capital in Q1 2018, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Arcus Biosciences: 2,236,387 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 77% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $16M trimmed.

  • EcoR1 Capital's largest Q1 2018 buy was Arcus Biosciences: 2,236,387 shares worth $34.5M.
  • EcoR1 Capital added most to Wave Life Sciences in Q1 2018, an estimated $22M increase.
  • EcoR1 Capital's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $16M.
  • EcoR1 Capital fully exited MyoKardia, Inc. Common Stock in Q1 2018, selling an estimated $32.8M.
  • EcoR1 Capital's ten largest holdings make up 74% of its $997M portfolio in Q1 2018.
  • EcoR1 Capital opened 11 new positions and closed 10 in Q1 2018.
  • EcoR1 Capital's portfolio value rose 12% quarter-over-quarter to $997M.

Based on EcoR1 Capital's 13F filing for Q1 2018, filed 15 May 2018.